Cancer Pain Therapeutics Market Size, Share and Growth Outlook, 2026

Cancer Pain Therapeutics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cancer Pain Therapeutics Market size is forecast to increase from $7.61 Billion in 2026 to $11.95 Billion in 2034 at a CAGR of 5.8% between 2026 and 2034.

The Cancer Pain Therapeutics market report provides detailed analysis and outlook of Cancer Pain Therapeutics segments including By Drug Class (Opioids, Non-Opioids, Adjuvant Analgesics, Targeted Pain Therapies, Medical Cannabinoids), By Route of Administration (Oral, Parenteral, Transdermal, Sublingual & Buccal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cancer Pain Therapeutics Industry Overview

Non-Opioid Sodium Channel Modulators Advancing Cancer Pain Management

The cancer pain therapeutics industry is increasingly focused on developing non-opioid treatment options capable of addressing complex cancer-associated pain while avoiding the risks of opioid dependence. A notable development is Dogwood Therapeutics’ strategic partnership with PRIDCor Therapeutics, valued at up to $100 million, which enabled the company to redirect substantial resources toward the advancement of Halneuron®. The investigational therapy is a highly selective voltage-gated sodium channel NaV 1.7 modulator designed to interrupt pain signaling pathways associated with cancer and cancer treatments. Initial clinical studies demonstrated meaningful reductions in chronic chemotherapy-induced neuropathic pain (CINP) as well as generalized cancer pain transmission. Unlike traditional opioid analgesics, Halneuron® is specifically designed to provide pain relief without creating opioid dependency risks. This focus on targeted neurological pain modulation reflects a broader industry shift toward safer, mechanism-based therapies for oncology patients experiencing persistent and treatment-related pain.

Novel FABP5 Inhibitors Expanding Neuropathic Pain Treatment Options

Innovation in cancer pain therapeutics is also being driven by the exploration of new molecular targets involved in inflammation and neuropathic pain signaling. Artelo Biosciences reported progress for ART26.12, a non-opioid and non-steroidal analgesic candidate that functions as a selective Fatty Acid Binding Protein 5 (FABP5) inhibitor. Following successful completion of first-in-human Phase 1 single ascending dose studies demonstrating favorable safety and predictable pharmacokinetic characteristics, the company advanced preparations for multiple ascending dose clinical trials. Preclinical findings published in the European Journal of Pain confirmed that ART26.12 effectively regulates pro-inflammatory lipid-signaling pathways associated with neuropathic pain. The compound demonstrated the ability to block severe neuropathic pain transmission induced by oncological treatments, highlighting the growing potential of lipid-signaling modulation as a therapeutic strategy for managing cancer-related pain syndromes.

Oncology Therapeutics Targeting the Root Causes of Severe Cancer Pain

The industry is increasingly recognizing that effective cancer pain management extends beyond direct analgesic intervention to include therapies that prevent disease progression responsible for severe pain generation. Daiichi Sankyo’s revised five-year business strategy places significant emphasis on expanding clinical indications for its antibody-drug conjugate (ADC) portfolio, including Enhertu and Ifinatamab Deruxtecan. A major focus of these expansion efforts is the prevention of secondary bone metastases and the reduction of tumor-induced skeletal fractures. These complications are among the most common causes of severe opioid-refractory pain in patients with advanced breast and lung cancers. By targeting the underlying oncological mechanisms that contribute to skeletal destruction and metastatic progression, ADC-based therapies are becoming increasingly relevant within comprehensive cancer pain management frameworks. This trend highlights the growing integration of disease-modifying oncology treatments with supportive care strategies aimed at improving patient quality of life.

Cancer Pain Therapeutics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cancer Pain Therapeutics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Pfizer Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca plc, GlaxoSmithKline plc (GSK), Medtronic plc, AbbVie Inc., Sun Pharmaceutical Industries Ltd.. The Cancer Pain Therapeutics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cancer Pain Therapeutics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cancer Pain Therapeutics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cancer Pain Therapeutics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cancer Pain Therapeutics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cancer Pain Therapeutics Market Competitive Benchmarking and Company Analysis

Leading companies in Cancer Pain Therapeutics industry include- Pfizer Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca plc, GlaxoSmithKline plc (GSK), Medtronic plc, AbbVie Inc., Sun Pharmaceutical Industries Ltd.. The Cancer Pain Therapeutics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cancer Pain Therapeutics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cancer Pain Therapeutics market remains one of the strongest-performing segments in the country.
The US Cancer Pain Therapeutics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cancer Pain Therapeutics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cancer Pain Therapeutics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cancer Pain Therapeutics markets

Canada's strong Cancer Pain Therapeutics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cancer Pain Therapeutics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cancer Pain Therapeutics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cancer Pain Therapeutics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cancer Pain Therapeutics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cancer Pain Therapeutics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cancer Pain Therapeutics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cancer Pain Therapeutics sales through 2034

France Cancer Pain Therapeutics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cancer Pain Therapeutics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cancer Pain Therapeutics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cancer Pain Therapeutics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cancer Pain Therapeutics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cancer Pain Therapeutics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cancer Pain Therapeutics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cancer Pain Therapeutics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cancer Pain Therapeutics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cancer Pain Therapeutics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cancer Pain Therapeutics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cancer Pain Therapeutics Market Segmentation

By Drug Class
Opioids
Non-Opioids
Adjuvant Analgesics
Targeted Pain Therapies
Medical Cannabinoids
By Route of Administration
Oral
Parenteral
Transdermal
Sublingual & Buccal
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Top Companies in Cancer Pain Therapeutics Industry

Pfizer Inc.
Novartis AG
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
AstraZeneca plc
GlaxoSmithKline plc (GSK)
Medtronic plc
AbbVie Inc.
Sun Pharmaceutical Industries Ltd.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa